MF59佐剂流感疫苗改善低预存抗体儿童的异源免疫应答
该研究基于一项临床试验的子集分析,比较MF59佐剂与非佐剂流感疫苗在儿童中对疫苗株及漂移株的抗体应答。中和试验显示,在预存抗体滴度较低的受试者中,佐剂疫苗不仅提高对疫苗株的中和抗体应答,也增强对漂移株的交叉反应抗体应答,不受年龄或接种史影响。结果提示佐剂疫苗对低预存抗体者具有免疫学获益及潜在效力获益。
要点
- MF59佐剂疫苗在低预存抗体者中增强对疫苗株的中和抗体应答。
- 佐剂疫苗还提高对漂移株的交叉反应抗体应答,不受年龄或接种史影响。
- 结果提示佐剂疫苗对低预存抗体者可能带来效力获益。
核心结论
- MF59佐剂疫苗在预存抗体滴度较低的受试者中改善对疫苗株和漂移株的交叉反应抗体应答,提示免疫学获益和潜在效力获益。
研究设计与样本
- 一项临床试验的子集分析,选取代表不同年龄和/或免疫史的受试者,检测对疫苗A/H3N2株及抗原性匹配试验季节流行病毒的漂移株的抗体应答。
主要发现
- 中和试验显示,与无佐剂疫苗相比,MF59佐剂疫苗在预存抗体滴度较低的受试者中不仅改善对疫苗株的中和抗体应答,还改善对漂移株的交叉反应抗体应答,不受年龄或接种史影响。
临床怎么用
- 对预存抗体滴度较低的儿童,MF59佐剂流感疫苗可能提供更广的交叉保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination is the most effective approach to reduce the substantial morbidity and mortality caused by influenza infection. Vaccine efficacy is highly sensitive to antigenic changes causing differences between circulating and vaccine viruses. Adjuvants such as MF59 increase antibody-mediated cross-reactive immunity and therefore may provide broader seasonal protection. A recent clinical trial showed that an MF59-adjuvanted vaccine was more efficacious than a nonadjuvanted comparator in subjects < 2 years of age, although not in those ≥ 2 years, during influenza seasons in which the predominant circulating virus was an A/H3N2 strain that was antigenically different from the vaccine virus. This finding suggested that the increased efficacy of the adjuvanted vaccine in younger subjects may be mediated by strain cross-reactive antibodies. A subset of the trial population, representing subjects with distinct age and/or immunological history, was tested for antibody responses to the vaccine A/H3N2 strain as well as A/H3N2 drifted strains antigenically matching the viruses circulating during the trial seasons. The neutralizing tests showed that, compared with nonadjuvanted vaccine, the adjuvanted vaccine improved not only the neutralizing antibody response to the vaccine strain but also the cross-reactive antibody response to the drifted strains in subjects with lower preexisting antibody titers, regardless of their age or vaccine history. The results demonstrated an immunological benefit and suggested a potential efficacy benefit by adjuvanted vaccine in subjects with lower preexisting antibody responses.
引用
- Palladino G, Ferrari A, Music N, et al. Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine. Vaccine. 2021. PMID: 34393015. doi:10.1016/j.vaccine.2021.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。